



LYMPHOID NEOPLASIA

Comment on Lindahl et al, page 759

Distinct miRNA profile in prognosis of early CTCL

Mariusz A. Wasik | University of Pennsylvania

In this issue of *Blood*, Lindahl et al report that expression of 3 microRNAs (miRNAs) (miR-106b-5p, miR-148a-3p, and miR-338-3p) in tissues of the mycosis fungoides (MF) subtype of cutaneous T-cell lymphoma (CTCL) is highly predictive of disease progression.¹

This set of 3 miRNAs was more powerful in predicting MF progression than the clinical prognostic factors currently in use.² The Lindahl et al study is comprehensive and takes advantage of a large and very-well-characterized cohort of MF patients with long clinical follow-up. To a great extent, it is unique and well positioned to address an important diagnostic need for early identification of MF patients poised to experience disease progression.³ The results of the study may have an impact on the care of patients in the future by introducing miRNA pattern evaluation into routine diagnostic workup of MF biopsy specimens.

However, before this happens, a number of factors need to be considered. First, the results reflect findings in a genetically rather homogeneous Danish population; thus, validation of the prognostic ability of the 3-miRNA classifier needs to be performed in a more ethnically diverse group of patients. Second, the expression fold-difference of these miRNAs as progression predictors is rather small for 2 of the 3 markers (miR-106b-5p and miR-148a-3p), which makes it potentially quite difficult to apply the analysis as a routine diagnostic test. Of note, the identified set of 3 miRNAs has been found to be predictive of progression but is not diagnostic for MF, because the set

can also be expressed in inflammatory skin diseases such as psoriasis. This observation may not be unexpected, given the dominant inflammatory component at the early stage of MF,⁴ but it raises the question of which type of cells (reactive vs neoplastic) express the identified miRNA triad. This lack of specificity for MF limits the potential clinical utility of the miRNA triad to some degree. Finally, the mechanisms controlling expression of these miRNAs need to be elucidated, once their cellular source is established. Mechanistic evaluation of this kind may include exploring potential links, direct or indirect, to genetic alterations of the neoplastic cells. This important task may prove particularly challenging, given the vast mutational diversity reported in MF and Sézary syndrome, a type of CTCL closely related to MF.⁵⁻¹⁰

In summary, identification of the predictive set of 3 miRNAs holds promise of early stratification of MF patients into groups with high and low risk of progression. However, a number of questions need to be answered before the true significance of this novel classifier and its potential impact on clinical care of MF patients can be fully determined.

Conflict-of-interest disclosure: The author declares no competing financial interests. ■

REFERENCES

1. Lindahl LM, Besenbacher S, Rittig AH, et al. Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. *Blood*. 2018;131(7):759-770.
2. Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sézary syndrome. *Eur J Cancer*. 2013;49(13):2859-2868.
3. Litvinov IV, Tetzlaff MT, Thibault P, et al. Gene expression analysis in cutaneous T-cell lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. *Oncoimmunology*. 2017;6(5):e1306618.
4. Krejsgaard T, Lindahl LM, Mongan NP, et al. Malignant inflammation in cutaneous T-cell lymphoma—a hostile takeover. *Semin Immunopathol*. 2017;39(3):269-282.
5. Wang L, Ni X, Covington KR, et al. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. *Nat Genet*. 2015;47(12):1426-1434.
6. Ungewickell A, Bhaduri A, Rios E, et al. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. *Nat Genet*. 2015;47(9):1056-1060.
7. Sandoval J, Díaz-Lagares A, Salgado R, et al. MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma. *J Invest Dermatol*. 2015;135(4):1128-1137.
8. McGirt LY, Jia P, Baerenwald DA, et al. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. *Blood*. 2015;126(4):508-519.
9. da Silva Almeida AC, Abate F, Khiabani H, et al. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. *Nat Genet*. 2015;47(12):1465-1470.
10. Kiel MJ, Sahasrabudde AA, Rolland DC, et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome. *Nat Commun*. 2015;6:8470-8478.

DOI 10.1182/blood-2017-12-821520

© 2018 by The American Society of Hematology